Alemany S, Avella-Garca C, Liew Z, Garca-Esteban R, Inoue K, Cadman T, Lpez-Vicente M, Gonzlez L, Riao Galn I, Andiarena A, Casas M, Margetaki K, Strandberg-Larsen K, Lawlor DA, El Marroun H, Tiemeier H, Iiguez C, Tardn A, Santa-Marina L, Jlvez J, Porta D, Chatzi L, Sunyer J
Check out this collection of content on GLP1 therapies, which includes a podcast with Prof Daniel Drucker that I co-hosted
Semaglutide reduces appetite, making it easier for people to maintain a healthy, low-calorie diet
Not recommended during pregnancy or breastfeeding
Despite the rising prevalence of obesity, only 32 percent of Canadians correctly identified that Health Canada classifies obesity as a progressive chronic disease, as reported by Phoenixs survey of over 1,500 Canadians
Cagrilintide occupies a special position in current obesity research because, as the first long-acting amylin analogue, it opens up a distinct receptor axis